For Prescribing Information, please click here. Adverse Event Reporting Information is found at the
bottom of the page.

This page has been funded and created by AstraZeneca and the content is intended for GB HCPs only.

On average, 15 in every 1,000 patients on a dispensing practice list were found
to be appropriate for a dapagliflozin initiation.*

Dapagliflozin is indicated in adult patients for insufficiently controlled T2D, symptomatic chronic HF and CKD.

What is the dapagliflozin patient identification resource?

This is a series of searches made for GP Systems (EMIS, SystmOne and Vision) which allows you to identify
potential patients who are within licence and could benefit from dapagliflozin.

How do I get the clinical searches?

Easy, head to the links at the bottom of this page or click here. It takes less than ten minutes to download
and run the searches!

Now what do I do? How do I get the searches into my clinical system?

There are written instructions provided once you register for the resource but the easiest way is to watch the video below.

This video is for SystemOne, however, the process is very similar for EMIS and Vision (Bespoke implementation
instructions are available on the links at the end of each clinical system).

I have run the searches now what should I do?

Patients are collated into 6 different cohorts dependent on their clinical diagnosis. You can then decide on how best to review each patient cohort, including how best to utilise your general practice team, to ensure that these patients get appropriately prescribed dapagliflozin.

Do I need to run the tool again?

You can run the tool as many times as you want, however, each time make sure you get the latest version by going to the website to get the latest version.

Further information:

Official link to the Dapagliflozin Patient Identification Resource: Access here

Initiation and patient resources: here

Contact AstraZeneca for further support: here

Dispex Brand Comparisons – Gliflozins: Learn more here

Dispex Membership: Learn more here

*across a sample of 5 dispensing practices, an average of 198 patients out of 13,619 [average list size] were identified by the dapagliflozin patient identification resource to be eligible for an initiation.

1. AstraZeneca, Data on file, REF-197868

GB-49154 | DOP: October 2023